Related Experiment Video
Updated: Jun 26, 2026
Standardized Histomorphometric Evaluation of Osteoarthritis in a Surgical Mouse Model
Published on: May 6, 2020
New approach to testing treatments for osteoarthritis: FastOA
David Felson1, Martin K Lotz2, Yuxuan Jin3
1Boston University School of Medicine, Boston, Massachusetts, USA dfelson@bu.edu.
Abstract:
Animal models of post traumatic osteoarthritis have shown many promising treatments for disease, but human trials have mostly failed to identify effective treatments. This viewpoint suggests that the frequent failure of drug and treatment development in osteoarthritis is due, in part, to the advanced stage of disease of patients in trials and suggests that mirroring the animal model approach might be more successful. It suggests a path forward by enriching trial enrollees with those likely to develop post traumatic OA quickly.
Insights
Developing treatments for post-traumatic osteoarthritis (PTOA) often fails in human trials. This viewpoint suggests focusing on early-stage PTOA patients, similar to animal models, to improve treatment success rates.
Area of Science:
- Orthopedics
- Rheumatology
- Translational Medicine
Background:
- Animal models show promise for post-traumatic osteoarthritis (PTOA) treatments.
- Human clinical trials for PTOA therapies have largely failed to demonstrate efficacy.
Purpose of the Study:
- To analyze the reasons for high failure rates in PTOA drug and treatment development.
- To propose a novel strategy for improving the success of PTOA clinical trials.
Main Methods:
- Review of current challenges in osteoarthritis (OA) clinical trial design.
- Proposal for a paradigm shift in patient selection for PTOA studies.
Main Results:
- A significant factor in trial failure is the advanced stage of OA in human participants.
- Current trial designs may not accurately reflect the early disease progression observed in animal models.
Conclusions:
- Enrolling patients likely to develop PTOA rapidly could enhance trial outcomes.
- Aligning human trial enrollment with animal model disease stages may improve therapeutic development for PTOA.
